Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SHOULDER, METAL/POLYMER ELBOW PROSTHESES AND PLASTER OF PARIS SHOULD GET CLASS II STATUS, WITH METAL/METAL ELBOWS REMAINING IN CLASS III -- ORTHOPEDIC PANEL

This article was originally published in The Gray Sheet

Executive Summary

Shoulder and metal/polymer elbow prostheses should be downclassified to Class II, FDA's Orthopedic Devices Panel concluded at a Jan. 12 meeting in Gaithersburg, Maryland. However, the advisory committee recommended that metal/metal elbow prostheses remain in Class III, given a lack of data on the novel devices.

You may also be interested in...



Vemedia Acquires GSK Brands In Italy, Strikes Deal For GI Product In Spain

GSK has offloaded a further two brands, this time in Italy, giving Netherlands-based Vemedia the opportunity to bolster its portfolio in the country. Vemedia has also added to its offering in Spain by striking a separate deal with Puerto Galiano.

EU Preserves Status Quo On Drugs Under Additional Monitoring

The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.

Meitheal Gets US Enoxaparin Approval

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.

UsernamePublicRestriction

Register

MT009484

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel